- Home
- MPV vs CHRS Comparison
MPV vs CHRS Comparison
Compare MPV & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MPV | CHRS |
|---|---|---|
| Founded | 1988 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 201.1M | 186.0M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | MPV | CHRS |
|---|---|---|
| Price | $19.48 | $1.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.51 |
| AVG Volume (30 Days) | 25.2K | ★ 987.2K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 8.71% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.71 | 1.34 |
| Revenue | N/A | ★ $277,728,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $67.29 |
| P/E Ratio | $9.35 | ★ $1.04 |
| Revenue Growth | N/A | ★ 152.07 |
| 52 Week Low | $11.18 | $0.71 |
| 52 Week High | $16.42 | $1.89 |
Technical Indicators
Market Signals| Indicator | MPV | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 45.73 | 53.32 |
| Support Level | $19.35 | $1.31 |
| Resistance Level | $20.21 | $1.45 |
| Average True Range (ATR) | 0.31 | 0.09 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 30.27 | 77.40 |
Price Performance
Historical ComparisonAbout MPV Barings Participation Investors
Barings Participation Investors is a diversified closed-ended management investment company. The Trust's investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. Its principal investments are privately placed, below-investment grade, long-term debt obligations including bank loans and mezzanine debt instruments. The company invests in various sectors such as aerospace and defense; automotive; building materials; consumer products and others.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.